Company news

Share this article:
San Diego, CA-based Adventrx Pharmaceuticals announced that it will terminate a total of nine employees, 27% of its workforce, including one sales position as part of a comprehensive restructuring initiative. Evan M. Levine resigned his positions as CEO and president, effective October 17, 2008. Going forward, the company said that it will focus its resources solely on the development and regulatory approvals of ANX-530 (vinorelbine emulsion) and ANX- 514 (docetaxel emulsion). The company has discontinued active work on all product candidates other than ANX-530 and ANX-514, including its CoFactor program. Patients currently receiving CoFactor will continue to receive treatment.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.